|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As the opioid epidemic heats up, these companies have most at stake.
The Indianapolis-based company said it had profit of 95 cents per share. Earnings, adjusted for restructuring costs, came to $1.11 per share. The results topped Wall Street expectations. The average estimate ...
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.